Exploring the druggability of genes from the TPX2/TTK network, we identified several potentially therapeutic targets in CRC, including AURKA, TOP2A, CDK1, ADRM1, TOP1, PSMA7, RRM2, KIF11, CHEK1, CDC7, XPO1, PPAT, PLK4, and BIRC5. This evidence concerns the gene TTK and colorectal carcinoma.